LON:DNL Diurnal Group (DNL) Share Price, News & Analysis → Urgent alert: open this for a huge profit potential (From Timothy Sykes) (Ad) Free DNL Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range 27.30▼ 27.3052-Week Range N/AVolume145,283 shsAverage Volume483,617 shsMarket Capitalization£46.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Diurnal Group alerts: Email Address Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About Diurnal Group Stock (LON:DNL)Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency. It also develops Chronocort, which completed Phase II clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early-stage pipeline products comprise Ditest, a native oral testosterone product, which has completed phase I clinical trial for the treatment of classical hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (triiodothyronine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.Read More Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. DNL Stock News HeadlinesMay 28, 2024 | msn.comH-DNL gets four teams selected for CIF NorCal playoffsMay 16, 2024 | msn.comPrep sports | 9 H-DNL teams still remain after round one of NCS baseball, softball playoffsFebruary 6, 2024 | morningstar.comDa Nang Port Logistics JSC DNLDecember 9, 2023 | morningstar.comD&L Industries IncAugust 23, 2023 | investing.comD&L Industries Inc (DNL)March 22, 2023 | wsj.comD&L Industries Inc.October 28, 2022 | finance.yahoo.comForm 8.3 - Diurnal Group plcAugust 30, 2022 | markets.businessinsider.comForm 8.3 - Maitland Institutional Services Limited: Re Diurnal Group plcAugust 30, 2022 | marketwatch.comDiurnal Group Agrees to High Premium $56.5 Mln Takeover by Neurocrine BiosciencesAugust 16, 2022 | finance.yahoo.comDiurnal Group plc (DNL.L)March 22, 2022 | proactiveinvestors.com.auAIQ boosted by deal to supply NFT marketplace in Hong KongMarch 22, 2022 | proactiveinvestors.comDiurnal drops after losses nearly double and it seeks fundingMarch 22, 2022 | proactiveinvestors.comDiurnal nosedives on need for further fundingMarch 9, 2022 | proactiveinvestors.com.auDiurnal dips as bosses give investor presentationMarch 2, 2022 | morningstar.comDiurnal Group Says Male Hypogonadism Treatment Study to Be DelayedNovember 16, 2021 | marketwatch.comDiurnal Group's Alkindi Drug Approved for Use in Children, Adolescents in SwitzerlandNovember 13, 2021 | finance.yahoo.comShareholders May Be More Conservative With Diurnal Group plc's (LON:DNL) CEO Compensation For NowOctober 11, 2021 | marketwatch.comDiurnal Group Ditest Clinical Trial Results PublishedSeptember 28, 2021 | markets.businessinsider.comHardman & Co Research : Diurnal Group (DNL): All set for three pivotal trialsSeptember 16, 2021 | markets.businessinsider.comDiurnal Group PLC : Commercial launch of Efmody in the UKSeptember 16, 2021 | finanznachrichten.deHardman & Co Research: Diurnal Group (DNL): All set for three pivotal trialsSeptember 16, 2021 | finanznachrichten.deHardman & Co Research: Diurnal Group (DNL): All set for three pivotal trialsSeptember 15, 2021 | finance.yahoo.comHere's Why We're Not Too Worried About Diurnal Group's (LON:DNL) Cash Burn SituationAugust 8, 2021 | markets.businessinsider.comDiurnal Group PLC : Business and Trading UpdateJuly 24, 2021 | news.yahoo.comHartwick Seminary Summer Institute of Theology to mark 30 yearsSee More Headlines Receive DNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diurnal Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/15/2020Today6/09/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:DNL CUSIPN/A CIKN/A Webwww.diurnal.co.uk Phone+44-29-20682069FaxN/AEmployees33Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.77 Current Ratio5.23 Quick Ratio4.16 Sales & Book Value Annual Sales£4.68 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.81 Book ValueGBX 12.70 per share Price / BookN/AMiscellaneous Outstanding Shares169,720,000Free FloatN/AMarket Cap£46.33 million OptionableNot Optionable BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Richard Edward Bungay A.C.A. (Age 53)ACA, B.Sc., BSc, Interim CEO, CFO, Company Sec. & Director Comp: $338kProf. Richard RossChief Scientific Officer & Exec. DirectorMr. Stewart JonesOperations DirectorMr. John Porter MBBSPh.D., Chief Medical OfficerMr. David Bevan (Age 55)Chief Bus. Officer Key CompetitorsAlliance PharmaLON:APHBeximco PharmaceuticalsLON:BXPAnimalcare GroupLON:ANCRECO Animal Health GroupLON:EAHCeladon PharmaceuticalsLON:CELView All Competitors DNL Stock Analysis - Frequently Asked Questions How were Diurnal Group's earnings last quarter? Diurnal Group plc (LON:DNL) issued its quarterly earnings results on Tuesday, September, 15th. The company reported ($4.30) EPS for the quarter, topping analysts' consensus estimates of ($6.70) by $2.40. What other stocks do shareholders of Diurnal Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Diurnal Group investors own include Allena Pharmaceuticals (ALNA), Abercrombie & Fitch (ANF), Ampliphi Biosciences (APHB), Cerecor (CERC), Revolution Lighting Technologies (RVLT), Spero Therapeutics (SPRO), SRC Energy (SRCI), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF) and AcelRx Pharmaceuticals (ACRX). How do I buy shares of Diurnal Group? Shares of DNL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:DNL) was last updated on 6/9/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes | SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored📈 Alert: Gold Reaches New All Time High Amidst Inflation DataCentral Banks Have bought More Gold in the last 2 years than in all of history combined. That's right, the SAM...All American Assets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diurnal Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Diurnal Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.